What is the first-line treatment of IgG4-related orbital inflammation?
Clinical scenario
IgG4-related orbital inflammation (IgG4-ROD) is a fibro-inflammatory condition of the orbit requiring a structured, evidence-based treatment approach. The protocol covers initial therapy selection and the clinical benchmarks used to determine whether treatment is succeeding.
Treatment approach — partial overview
Glucocorticoids form the cornerstone of first-line therapy for IgG4-ROD. The route of administration is guided by disease location and individual clinical factors. The complete regimen — including sequencing, monitoring parameters, and escalation criteria — is available in the full protocol.
Treatment goals
- Response within weeks of initiating therapy
- Reduction in the size of orbital masses
- Improvement of orbital and systemic symptoms
- Marked decrease in serum IgG4
References
- Glucocorticoids are the first-line treatment for most patients with IgG4-ROD.
- Common approach to the treatment IgG4-ROD with systemic corticosteroid was initiated orally with prednisolone 0.6 mg/kg/day for 2–4 weeks and then tapered by 5 mg every 2–4 weeks.
- It generally took 3–6 months to discontinue steroid treatment.
- Besides, intraorbital injection of glucocorticoids had been reported as an alternative treatment approach for IgG4-ROD centered in anterior orbit to avoid systemic immunosuppression.
- The vast majority of patients with IgG4-ROD respond well to glucocorticoids within weeks, typically with reductions in the size of masses, improvements of symptoms, and often a marked decrease in serum IgG4.
DOI: 10.4103/tjo.tjo_12_17
View source ↗